IntelliDOT Corp. received FDA 510(k) clearance for the IntelliDOT Blood Product Administration (IntelliDOT BPA) for commercial sale.

June 24, 2008 - IntelliDOT Corp. said yesterday the FDA granted 510(k) clearance for the IntelliDOT Blood Product Administration (IntelliDOT BPA) for commercial sale.

June 23, 2008 - For more than a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke, but its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.

Now, a new paper published recently online in Nature Medicine reveals why tPA has these limitations. It also gives tantalizing evidence about how those problems might be overcome, if a stroke victim first takes a drug currently used to treat leukemia.

June 20, 2008 - Freescale Semiconductor and Monebo Technologies recently forged a partnership to deliver a comprehensive platform for medical equipment using electrocardiogram (ECG) on a chip technology to enable medical equipment manufacturers to develop easy-to-use ECG monitoring tools.


Human error is one of patient safety’s biggest enemies and while clinicians try not to make mistakes, they frequently have their attention pulled in several directions at once. Computers on the other hand can be programmed to look for mistakes to help avert problems, which is the main reason advocates say electronic health records (EHRs) are needed to make vast improvements in patient safety.

June 19, 2008 - Biopure Corp. said this week the U.S. Naval Medical Research Center (NMRC) submitted a new protocol for review by the FDA for a Phase 2 clinical trial of Hemopure (hemoglobin glutamer - 250 - bovine), or HBOC-201, for resuscitation of casualties with severe traumatic hemorrhagic shock without availability of blood transfusions. The proposed trial hypotheses is that for such casualties Hemopure substitute blood will improve survival and other clinical parameters, and will be relatively safe and well tolerated, in comparison with standard fluid.

June 19, 2008 – HemoCue AB, a point-of-care diagnostic test manufacturer and wholly owned subsidiary of Quest Diagnostics Inc. said its HemoCue Albumin 201 System is the first quantitative point-of-care test for screening, diagnosing and monitoring microalbuminuria to be granted a CLIA waiver by the FDA.

June 18, 2008 – Bracco Diagnostics showcased its Cardiac PET Perfusion Imaging with CardioGen-82, a Rubidium Rb 82 generator and emphasized the advantages of cardiac PET Perfusion Imaging over the current SPECT, at the Society of Nuclear Medicine's 55th Annual Meeting.

June 18, 2008 - New imaging software that will allow physicians to more accurately diagnose and treat heart failure patients has been licensed by Emory University to Syntermed, an Atlanta-based nuclear medicine imaging and informatics software company.

June 18, 2008 - Researchers using positron emission tomography (PET) are able to see changes in coronary blood vessels, offering hope that those at risk of cardiac deaths caused by disease in the heart’s vessels can receive earlier treatment and prolong life.

As many as 50 percent of all cardiac deaths due to disease in the heart’s vessels occur in individuals with no prior history or symptoms of heart disease. In addition, standard coronary risk factors may fail to explain up to 50 percent of cardiovascular events.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now